Phosphorylation, Signaling, and Cancer: Targets and Targeting.
作者信息
Marmiroli Sandra, Fabbro Doriano, Miyata Yoshihiko, Pierobon Mariaelena, Ruzzene Maria
机构信息
Cellular Signaling Unit, Department of Surgery, Medicine, Dentistry and Morphology, University of Modena and Reggio Emilia, Largo del Pozzo, 71-41100 Modena, Italy.
Piqur Therapeutics, Hochbergerstrasse 60C, 4057 Basel, Switzerland.
出版信息
Biomed Res Int. 2015;2015:601543. doi: 10.1155/2015/601543. Epub 2015 Oct 21.
Abstract
摘要
相似文献
1
Phosphorylation, Signaling, and Cancer: Targets and Targeting.
Biomed Res Int. 2015;2015:601543. doi: 10.1155/2015/601543. Epub 2015 Oct 21.
2
Mechanisms of drug inhibition of signalling molecules.
Nature. 2006 May 25;441(7092):457-62. doi: 10.1038/nature04874.
3
The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).
Int J Mol Med. 2017 Aug;40(2):271-280. doi: 10.3892/ijmm.2017.3036. Epub 2017 Jun 22.
4
Protein kinases as targets for cancer treatment.
Pharmacogenomics. 2007 Aug;8(8):1005-16. doi: 10.2217/14622416.8.8.1005.
5
Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future.
Expert Rev Proteomics. 2018 Nov;15(11):851-853. doi: 10.1080/14789450.2018.1531709. Epub 2018 Oct 12.
6
Advancing the kinase field: new targets and second generation inhibitors.
J Med Chem. 2015 Jan 8;58(1):1. doi: 10.1021/jm5018708. Epub 2014 Dec 9.
7
Targeting cancer with kinase inhibitors.
J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1.
8
Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
J Drug Target. 2016;24(3):192-211. doi: 10.3109/1061186X.2015.1068319. Epub 2015 Jul 27.
9
My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11579-11586. doi: 10.1073/pnas.1816012116. Epub 2019 May 10.
10
Endpoint of cancer treatment: targeted therapies.
Asian Pac J Cancer Prev. 2014;15(11):4395-403. doi: 10.7314/apjcp.2014.15.11.4395.
引用本文的文献
1
A Novel Missense Variant of in Juvenile Polyposis Syndrome: Assessment of Structural and Functional Alternations.
Hum Mutat. 2025 Feb 18;2025:7317429. doi: 10.1155/humu/7317429. eCollection 2025.
2
Post-transcriptional regulation of BIRC5/survivin expression and induction of apoptosis in breast cancer cells by tristetraprolin.
RNA Biol. 2024 Jan;21(1):1-15. doi: 10.1080/15476286.2023.2286101. Epub 2023 Dec 18.
3
Pan-cancer Landscape of the RUNX Protein Family Reveals their Potential as Carcinogenic Biomarkers and the Mechanisms Underlying their Action.
J Transl Int Med. 2022 Jul 10;10(2):156-174. doi: 10.2478/jtim-2022-0013. eCollection 2022 Jun.
4
Function of Deptor and its roles in hematological malignancies.
Aging (Albany NY). 2021 Jan 7;13(1):1528-1564. doi: 10.18632/aging.202462.
5
In Search of Outliers. Mining for Protein Kinase Inhibitors Based on Their Anti-Proliferative NCI-60 Cell Lines Profile.
Molecules. 2020 Apr 11;25(8):1766. doi: 10.3390/molecules25081766.
6
Quantitative Phosphoproteomic Analysis Reveals Key Mechanisms of Cellular Proliferation in Liver Cancer Cells.
Sci Rep. 2017 Sep 7;7(1):10908. doi: 10.1038/s41598-017-10716-0.
7
Phosphoproteome Discovery in Human Biological Fluids.
Proteomes. 2016 Dec 1;4(4):37. doi: 10.3390/proteomes4040037.
8
Epidermal Growth Factor Signaling towards Proliferation: Modeling and Logic Inference Using Forward and Backward Search.
Biomed Res Int. 2017;2017:1809513. doi: 10.1155/2017/1809513. Epub 2017 Jan 16.
本文引用的文献
1
Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.
Biochem J. 2015 Nov 1;471(3):415-30. doi: 10.1042/BJ20141127. Epub 2015 Sep 8.
2
Ten things you should know about protein kinases: IUPHAR Review 14.
Br J Pharmacol. 2015 Jun;172(11):2675-700. doi: 10.1111/bph.13096. Epub 2015 Mar 24.
3
Advances in kinase targeting: current clinical use and clinical trials.
Trends Pharmacol Sci. 2014 Nov;35(11):604-20. doi: 10.1016/j.tips.2014.09.007. Epub 2014 Oct 10.
4
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.
Leukemia. 2014 Nov;28(11):2197-205. doi: 10.1038/leu.2014.123. Epub 2014 Apr 4.
5
Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.
Future Med Chem. 2014 Apr;6(5):541-61. doi: 10.4155/fmc.13.216.
6
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.
Cancer Discov. 2013 Dec;3(12):1345-54. doi: 10.1158/2159-8290.CD-13-0063. Epub 2013 Nov 21.
7
Kinase drug discovery--what's next in the field?
ACS Chem Biol. 2013 Jan 18;8(1):96-104. doi: 10.1021/cb300610s. Epub 2012 Dec 31.
8
Targeting kinases for the treatment of inflammatory diseases.
Expert Opin Drug Discov. 2010 Sep;5(9):867-81. doi: 10.1517/17460441.2010.504203. Epub 2010 Jul 15.
9
Tec family kinases in inflammation and disease.
Int Rev Immunol. 2012 Apr;31(2):87-103. doi: 10.3109/08830185.2012.670334.
10
Targeting cancer with small-molecular-weight kinase inhibitors.
Methods Mol Biol. 2012;795:1-34. doi: 10.1007/978-1-61779-337-0_1.
Zotero 插件